What Kinvard Bio does

Kinvard Bio is a clinical-stage biotechnology company developing a novel class of ribosome-targeting antibiotics called oxepanoprolinamides (OPPs). The company is a spin-out from Andrew G. Myers's laboratory at Harvard University's Department of Chemistry and Chemical Biology, founded with the explicit goal of combating antimicrobial resistance (AMR). Its core technology is a proprietary synthetic chemistry platform that produces bridged macrobicyclic compounds preorganized for optimal binding within the Peptidyl Transferase Center of the bacterial ribosome, demonstrating up to 300-fold greater binding affinity than traditional ribosome-targeting antibiotics such as clindamycin and bypassing a broad range of pre-existing resistance mechanisms.

The company's portfolio includes the lead compound Cresomycin and three pipeline candidates: KV-001 (lead optimization, targeting HABP/VABP and cUTI with a focus on Gram-negative bacteria), KV-002 (advancing toward IND for CABP and ABSSSI), and KV-003 (discovery stage, targeting NTM-LD chronic respiratory infections). The OPPs are designed for both intravenous and oral administration, enabling IV-to-oral step-down therapy and supporting outpatient management of chronic infections. The company intends to serve hospitals, healthcare providers, and ultimately patients with drug-resistant acute and chronic bacterial infections.

Kinvard Bio's revenue model is presently that of a preclinical drug developer: capital is sourced from non-dilutive grants (CARB-X) and seed equity (Kineticos Life Sciences), with future revenue expected from commercialization or out-licensing of approved antibiotics targeting indications including HABP/VABP, cUTI, CABP, ABSSSI, and NTM-LD. The company is headquartered in Raleigh, NC, operates with 1-10 employees, and has received approximately $3.9M in disclosed funding since launch in February 2025.

Name

Kinvard Bio

Legal name

Kinvard Bio Inc.

Website

https://kinvardbio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Kinvard Bio is a preclinical biotech spin-out from Harvard's Myers Lab developing oxepanoprolinamide (OPP) ribosome-targeting antibiotics, including lead compound Cresomycin, to treat drug-resistant acute and chronic bacterial infections in hospitals and outpatient settings.

Ownership category

akta.pro rank

Product category

Antibiotic Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)

Keywords

• Novel antibiotics
• Antimicrobial resistance drugs
• Ribosome-targeting therapeutics
• Antibacterial drug discovery
• Clinical-stage antibiotics

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: As a clinical-stage antibiotic development company, Kinvard Bio's primary revenue model is expected to come from commercialization of novel antibiotics upon regulatory approval. The company is developing multiple pipeline candidates (KV-001, KV-002, KV-003) targeting various bacterial infections including HABP/VABP, cUTI, CABP, ABSSSI, and NTM-LD.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Kinvard Bio is developing a new class of ribosome-targeting antibiotics called oxepanoprolinamides (OPPs), featuring the lead compound Cresomycin and pipeline candidates KV-001, KV-002, and KV-003. The OPPs use a novel bridged macrobicyclic ring system designed for optimal binding within the bacterial ribosome's Peptidyl Transferase Center, providing broad-spectrum activity against drug-resistant Gram-positive and Gram-negative pathogens including those associated with HABP/VABP, cUTI, CABP, ABSSSI, and nontuberculosis mycobacterial lung disease (NTM-LD).

Product overview

Kinvard Bio is a spin-out from Harvard University's Myers Lab developing a new class of ribosome-targeting antibiotics called oxepanoprolinamides (OPPs). The company's portfolio includes the lead compound Cresomycin and three pipeline candidates (KV-001, KV-002, KV-003) targeting various acute and chronic bacterial infections including HABP/VABP, cUTI, CABP, ABSSSI, and NTM lung disease. The OPP platform features a proprietary synthetic chemistry approach that enables broad-spectrum activity against both Gram-positive and Gram-negative bacteria while avoiding resistance mechanisms.

Differentiator

Problem solved

Functional benefit

Products and services

• Cresomycin An antibiotic preorganized for ribosomal binding that overcomes antimicrobial resistance, designed for both intravenous and oral routes of administration; the lead compound from Kinvard Bio's proprietary OPP chemistry platform.
• KV-001 Lead Optimization (LO) stage antibiotic candidate targeting Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) and complicated Urinary Tract Infections (cUTI), with focus on Gram-negative bacteria.
• KV-002 Pipeline candidate advancing through lead optimization (LO) towards IND stage, targeting Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI), covering all major pathogens including antibiotic-resistant strains.
• KV-003 Discovery stage pipeline candidate progressing OPPs into additional clinical indications including chronic respiratory diseases such as nontuberculosis mycobacterial lung disease (NTM-LD).

Quantifiable outcome

• Up to 300-fold greater binding affinity and potency compared to traditional ribosome-targeting antibiotics like clindamycin
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators1 record

Recent moves7 records

Expansion highlights5 records

Direct peers

• Cidara Therapeutics: Clinical-stage biotech developing novel anti-infectives including Cloudbreak antifungal-antibody conjugates. Comparable as a small-cap anti-infective developer pursuing novel mechanisms against resistant pathogens.
• Melinta Therapeutics: Antibiotic-focused company with marketed and pipeline agents (e.g., Baxdela, Orbactiv) targeting resistant bacterial infections including HABP/VABP and ABSSSI. Directly comparable in infectious disease focus and pipeline overlap with KV-001/KV-002.
• Iterum Therapeutics: Clinical-stage biotech developing oral and IV antibiotics (e.g., sulopenem) for resistant Gram-negative and urinary tract infections. Comparable in therapeutic focus on HABP/VABP and cUTI indications overlapping with KV-001.
• Paratek Pharmaceuticals: Developer of Nuzyra (omadacycline), a tetracycline antibiotic for CABP, ABSSSI, and cUTI. Directly comparable in therapeutic focus on the same indications targeted by KV-001 and KV-002.
• Nabriva Therapeutics: Antibiotic developer of Xenleta (lefamulin) for CABP and other community-acquired infections. Comparable in CABP/ABSSSI indication overlap with KV-002 and through leadership connection (Chairman Steve Gelone previously at Nabriva).
• VenatoRx Pharmaceuticals: Clinical-stage antibiotic developer focused on multidrug-resistant Gram-negative infections and β-lactamase inhibitors. Directly comparable as a small-cap biotech pursuing novel antibacterial chemistry against drug-resistant pathogens.

Emerging players

• BioVersys: Swiss clinical-stage biotech developing small molecules to address antimicrobial resistance, including adjunctive therapies that restore antibiotic activity. Comparable as an emerging AMR-focused company with novel antibacterial approaches.
• Adaptive Phage Therapeutics: Clinical-stage developer of phage-based therapies for drug-resistant bacterial infections. Comparable as an emerging modality-focused AMR company targeting overlapping resistant-infection patient populations.

Broad incumbents

• GSK: Major pharmaceutical company with a long-standing antibiotics franchise and active antimicrobial R&D. Relevant as a broad incumbent in infectious disease and through the leadership connection (Chairman Steve Gelone previously at GSK).
• Shionogi: Global pharmaceutical company with a leading antibiotics franchise including cefiderocol (Fetroja) for resistant HABP/VABP/UTI. Comparable as an established antibacterial innovator pursuing the same Gram-negative resistance indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kinvard-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kinvard Bio